Invention Grant
- Patent Title: Imidazo[4,5-c]quinolines as DNA-PK inhibitors
- Patent Title (中): 咪唑并[4,5-c]喹啉作为DNA-PK抑制剂
-
Application No.: US13819488Application Date: 2011-07-26
-
Publication No.: US09000153B2Publication Date: 2015-04-07
- Inventor: Thomas Fuchss , Werner Mederski , Frank Zenke
- Applicant: Thomas Fuchss , Werner Mederski , Frank Zenke
- Applicant Address: DE Darmstadt
- Assignee: Merck Patent GmbH
- Current Assignee: Merck Patent GmbH
- Current Assignee Address: DE Darmstadt
- Agency: Millen, White, Zelano & Branigan, P.C.
- Priority: DE102010035744 20100828
- International Application: PCT/EP2011/003744 WO 20110726
- International Announcement: WO2012/028233 WO 20120308
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61K31/5377 ; A61K31/437 ; A61K31/4745 ; A61K45/06 ; C07D215/42 ; C07D215/46
![Imidazo[4,5-c]quinolines as DNA-PK inhibitors](/abs-image/US/2015/04/07/US09000153B2/abs.jpg.150x150.jpg)
Abstract:
The invention relates to compounds of the formulae (I) and (II) in which R1, R2, R3, R4, R5, R8, X and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumors, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I).
Public/Granted literature
- US20130172337A1 Imidazo[4,5-c]quinolines as DNA-PK inhibitors Public/Granted day:2013-07-04
Information query